BiotechTube
Home/Pipeline/ABC-201

ABC-201

Endometriosis

PreclinicalActive

Key Facts

Indication
Endometriosis
Phase
Preclinical
Status
Active
Company
Abcely

About Abcely

Abcely is an early-stage biotech developing the world's first platform for orally active secretory IgA (sIgA) immunotherapies, targeting high-value markets in mucosal oncology and inflammatory diseases. Its proprietary technology aims to rapidly generate optimized drug candidates with superior mucosal targeting and penetration compared to conventional IgG antibodies. The company operates a dual business model of building its own pipeline and pursuing out-licensing opportunities, with three disclosed preclinical programs in colorectal cancer, endometriosis, and inflammatory bowel disease.

View full company profile

Therapeutic Areas

OncologyInflammatory DiseasesWomen's Health

Other Endometriosis Drugs

DrugCompanyPhase
Promarker™EndoProteomics InternationalLate‑stage validation
EV‑EndoCarthericsPreclinical
Endometriosis ProgramCyclana BioDiscovery
Endometriosis Genetic StudyJuneau BiosciencesDiscovery
Potential Diagnostic DevelopmentJuneau BiosciencesResearch
Endometriosis Discovery ProgramMetri BioDiscovery
Endometriosis Test SuiteHeranova LifesciencesPre-clinical
EndomTestKephera DiagnosticsCommercial (LDT)
ENDO-205EndoCyclic TherapeuticsPhase 1
Undisclosed ImmunotherapyApheon BiosciencePreclinical
FMCFimmCytePre-clinical
ERβ Modulator ProgramCadenza BioPreclinical